MedTrace Logo

Assessment of Methadone and Buprenorphine in Interstitial Fluid

NCT05546229 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2023-06-28

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to determine if common medications for opioid use disorder (i.e., buprenorphine/naloxone, buprenorphine, methadone) and their metabolites (norbuprenorphine \[a metabolite of buprenorphine\], buprenorphine-3-glucuronide \[B3G; a metabolite in buprenorphine\], ethylidene dimethyl diphenyl pyrrolidine \[EDDP; a metabolite of methadone\]) can be detected in the dermal interstitial fluid (i.e., fluid extracted from the surface of the skin). Additional subjects who are not prescribed or taking any of these medications will be included in this study to act as a comparison group

Conditions

Interventions

PROCEDURE

Microneedle based interstitial fluid collection

Interstitial fluid will be collected from the skin using microneedles and suction.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Cari Health Inc.

    lead OTHER

Principal Investigators

  • Mohammad Bari, MD · Synergy San Diego

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-14
Primary Completion
2022-10-31
Completion
2022-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05546229 on ClinicalTrials.gov